Patents Assigned to Signal Pharmaceuticals LLC
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 11590139
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: February 28, 2023
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Isotopologues of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
    Patent number: 11492332
    Abstract: Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: November 8, 2022
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Hon-Wah Man, Mohit Atul Kothare
  • Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
    Patent number: 11325890
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: May 10, 2022
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Mark A. Nagy, Stephen Norris, David A. Paisner, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
    Patent number: 11292796
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Further provided herein are methods for preparing a compound of formula (I), the method comprising contacting a compound of formula (III) with a compound of the following formula: R1-Y, in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1-R4, Y, the palladium catalyst and the base are as defined herein.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: April 5, 2022
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
  • Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
    Patent number: 11241430
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: February 8, 2022
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Marie Georges Beauchamps, Robert Hilgraf, Mohit Atul Kothare, Hon-Wah Man, Mark A. Nagy
  • Treatment of cancer with TOR kinase inhibitors
    Patent number: 11166950
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: November 9, 2021
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Heather Raymon, Rama K. Narla, Rajesh Chopra
  • Isotopologues of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
    Patent number: 10975039
    Abstract: Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: April 13, 2021
    Assignee: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Hon-Wah Man, Mohit Atul Kothare
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 10940152
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: March 9, 2021
    Assignee: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
    Patent number: 10919865
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: February 16, 2021
    Assignee: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Mark A. Nagy, Stephen Norris, David A. Paisner, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Isotopologues of 2-(tert butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
    Patent number: 10689351
    Abstract: Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: June 23, 2020
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Hon-Wah Man, Mohit Atul Kothare
  • Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
    Patent number: 10683298
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: June 16, 2020
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 10646493
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: May 12, 2020
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
    Patent number: 10590089
    Abstract: Provided are pharmaceutical compositions and dosage forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof. Also provided are methods of treating, managing, or preventing various disorders, such as diseases or disorders treatable or preventable by inhibition of a JNK pathway in mammals using such pharmaceutical compositions or dosage forms. Further provided are salts of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide and methods of preparation of such salts.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: March 17, 2020
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Nathan Andrew Boersen, Indrajit Ghosh, Lianfeng Huang, Daozhong Zou
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 10576085
    Abstract: Provided herein are methods for treating or preventing a cancer, including solid tumors and hematological cancers, comprising administering an effective amount of aminopurine compounds of formula (I), and compositions comprising an effective amount of such compounds.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: March 3, 2020
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: John F. Boylan, Gordon L. Bray, Ellen Filvaroff, Robert Hubbard, David Mikolon, Heather Raymon, Tao Shi, Tam M. Tran, Toshiya Tsuji, Lilly L. Wong, Shuichan Xu, Dan Zhu
  • Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
    Patent number: 10517873
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: December 31, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Marie Georges Beauchamps, Antonio Christian Ferretti, Robert Hilgraf, Mohit Atul Kothare, Hon-Wah Man, Mark A. Nagy, Kelvin Hin-Yeong Yong, Nanfei Zou
  • Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use
    Patent number: 10513519
    Abstract: Provided herein are formulations, solid forms and methods of use relating to (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: December 24, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Zheng Chen, Paul F. Fernandez, Tracy L. Gaebele, Lianfeng Huang, Matthew J. Jackson, Matthew M. Kreilein, Xiaoling Lu, Wenju Wu, Jean Xu
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 10398700
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: September 3, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Joshua Hansen, Dehua Huang, Robert Hubbard, Raj K. Raheja, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, JingJing Zhao
  • Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
    Patent number: 10391092
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 27, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Toshiya Tsuji, Rama K. Narla, Kristen Mae Hege
  • Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
    Patent number: 10266500
    Abstract: Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: April 23, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Brydon L. Bennett, Mercedes Delgado, Jan Elsner, Paul Erdman, Robert Hilgraf, Laurie Ann LeBrun, Meg McCarrick, Mark A. Nagy, Stephen Norris, David A. Paisner, Yoshitaka Satoh, Marianne Sloss, Jayashree Tikhe, Won Hyung Yoon
  • Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
    Patent number: 10226461
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: March 12, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Hon-Wah Man, Marie Georges Beauchamps, Mohit Atul Kothare, Nanfei Zou